NCT07286344 Effect of Fluoride Varnish Formulation on the Management of Dentin Hypersensitivity
| NCT ID | NCT07286344 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Concepcion, Chile |
| Condition | Hypersensitivity Dentin |
| Study Type | INTERVENTIONAL |
| Enrollment | 92 participants |
| Start Date | 2025-12-04 |
| Primary Completion | 2026-07-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 92 participants in total. It began in 2025-12-04 with a primary completion date of 2026-07-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized controlled clinical trial aims to determine whether different fluoride varnish formulations reduce dentin hypersensitivity (DH) in young adults diagnosed with DH. The primary purpose of this study is to evaluate the clinical effectiveness of two commercially available fluoride varnishes. The main questions this study aims to answer are: * Does Clinpro Clear® (aqueous base, 9,500 ppm NaF) lead to a greater reduction in dentin hypersensitivity compared with Duraphat® (rosin/resin base, 22,600 ppm NaF)? * Do these varnish formulations improve oral health-related quality of life and patient satisfaction? Researchers will compare a single application of Duraphat® with a single application of Clinpro Clear® to assess differences in hypersensitivity reduction, quality-of-life outcomes, and patient satisfaction. Participants will: * Receive one application of either Duraphat® or Clinpro Clear® under standardized clinical conditions. * Complete baseline and post-treatment evaluations, including: * Dentin hypersensitivity intensity using a visual analogue scale (VAS) * Air-blast response using the Schiff scale * Oral health-related quality of life using the OHIP-14 * Patient satisfaction using the CSAT survey
Eligibility Criteria
Inclusion Criteria: * Age between 18 and 40 years * Absence of systemic diseases with oral manifestations or requiring medications with antisialagogue effects * Fully dentate (excluding third molars or teeth extracted for orthodontic reasons) * Absence of periodontal disease, or periodontal condition in a stable state * Presence of at least one cervical lesion with a Schiff sensitivity score ≥ 1 * No previous treatment or restorative procedures on the target lesions (including no topical fluoride application within the last 6 months) Exclusion Criteria: * Patients requiring long-term use of NSAIDs or other analgesic/anti-inflammatory medications * Patients with allergy to milk proteins * Patients with allergy to organic resins or pine-derived substances * Pregnant or breastfeeding individuals * Patients with fixed orthodontic appliances in place
Contact & Investigator
Sebastian Muñoz, DDS
PRINCIPAL INVESTIGATOR
Department of Restorative Dentistry, Faculty of Dentistry, Universidad de Concepcion
Frequently Asked Questions
Who can join the NCT07286344 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 40 Years, studying Hypersensitivity Dentin. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07286344 currently recruiting?
Yes, NCT07286344 is actively recruiting participants. Contact the research team at proyectonccl@gmail.com for enrollment information.
Where is the NCT07286344 trial being conducted?
This trial is being conducted at Concepción, Chile.
Who is sponsoring the NCT07286344 clinical trial?
NCT07286344 is sponsored by University of Concepcion, Chile. The principal investigator is Sebastian Muñoz, DDS at Department of Restorative Dentistry, Faculty of Dentistry, Universidad de Concepcion. The trial plans to enroll 92 participants.